What is Septerna, Inc. (SEPN) stock price today?

Septerna, Inc. (SEPN) is currently trading at $37.37, up 1.28% today.

What is SEPN P/E ratio?

Septerna, Inc.'s P/E ratio is -69.94. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is SEPN return on equity (ROE)?

Septerna, Inc.'s return on equity (ROE) is -6.31%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Septerna, Inc.'s market cap?

Septerna, Inc. has a market capitalization of $1.68B.

NASDAQ · Biotechnology

Septerna, Inc. (SEPN) Stock

$37.37 +1.28% NASDAQ: SEPN Healthcare

Valuation

Metric	Value
Price	$37.37
Market Cap	$1.68B
P/E Ratio	-69.94
P/B Ratio	4.40
P/S Ratio	17.22
EPS (TTM)	$-1.95
52-Week High	$51.10
52-Week Low	$17.55
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-6.31%
ROA	-4.28%
ROCE	-8.93%
Gross Margin	99.42%
Operating Margin	-77.07%
Net Margin	-24.51%
Debt/Equity	0.06
Current Ratio	4.72

Annual Financials (USD)

Metric	2022	2023	2024	2025
Revenue	—	$0	$1.0M	$46.0M
Operating Profit	—	$2.0M	$-81.0M	$-81.0M
Net Profit	—	$4.0M	$-72.0M	$-49.0M
EPS	—	$0.03	$-1.93	$-1.10
Op Margin	—	1374.2%	-7518.4%	-175.8%

Balance Sheet (USD)

Metric	2022	2023	2024	2025
Total Assets	$36.0M	$131.0M	$457.0M	$596.0M
Total Liabilities	$80.0M	$169.0M	$37.0M	$214.0M
Cash	$31.0M	$88.0M	$238.0M	$121.0M
Borrowings	$1.0M	$13.0M	$25.0M	$24.0M

Latest News

Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors? Motley Fool · Jul 5, 2026 Is Septerna, Inc. (SEPN) Stock a Biotech Opportunity With a Potential First-in-Class Hypoparathyroidism Treatment? Insider Monkey · Jul 2, 2026 Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares? Motley Fool · Jun 30, 2026 Guggenheim Initiates Septerna at Buy With $52 Price Target MT Newswires · Jun 11, 2026 Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting Business Wire · Jun 8, 2026

Cash Flow (USD)

Metric	2022	2023	2024	2025
Operating Cash Flow	$-23.0M	$-39.0M	$-67.0M	$110.0M
Investing Cash Flow	$-3.0M	$19.0M	$-163.0M	$-230.0M
Financing Cash Flow	$0	$0	$0	$0
Net Cash Flow	$5.0M	$58.0M	$150.0M	$-117.0M
Free Cash Flow	$-25.0M	$-42.0M	$-70.0M	$110.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.39
EV / EBITDA	-41.27
FCF Yield	6.17%
Quick Ratio	4.99
Interest Coverage	0.00
Return 1Y	147.38%
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held3.18%

Institutions Held102.63%

Institutions Float Held106.00%

Institutional Holder	Shares	Report Date
RA Capital Management, L.P.	6,995,858	2026-03-31
Trv Gp V, LLC	6,215,591	2026-03-31
Driehaus Capital Management, LLC	4,395,572	2026-03-31
Trv Gp VI, LLC	4,211,659	2026-03-31
Samsara BioCapital, LLC	3,149,128	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BMEABiomea Fusion, Inc.	$1.37	+3.79%	-2.56	$99.05M	0.00%
GPCRStructure Therapeutics Inc.	$53.36	-3.23%	-20.21	$3.07B	0.00%
KLRAKailera Therapeutics, Inc.	$11.03	+10.32%	-6.27	$1.43B	0.00%
MAZEMaze Therapeutics, Inc.	$26.31	+1.66%	-9.65	$1.46B	0.00%
MBXMBX Biosciences, Inc.	$52.49	-1.43%	-24.38	$2.50B	0.00%

About Septerna, Inc.

Septerna, Inc. is led by CEO Jeffrey T. Finer, employs 75 people, headquartered in US, publicly traded since 2024.

Septerna, Inc. (SEPN) stock trades at $37.37 with a market capitalization of $1.68B. The stock is valued at a price-to-earnings (P/E) ratio of -69.94, price-to-book of 4.40, price-to-sales of 17.22. Over the past 52 weeks the stock has ranged between $17.55 and $51.10, and currently trades 26.9% below its 52-week high.

On profitability, Septerna, Inc. generates a return on equity (ROE) of -6.31%, return on capital employed of -8.93%, an operating margin of -77.07%, a net profit margin of -24.51%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.94 +0.03% JNJ Johnson & Johnson $259.48 +1.17% ABBV AbbVie Inc. $275.61 +1.17% MRK Merck & Company, Inc. Common Stock (new) $145.06 +1.88% UNH UnitedHealth Group Incorporated Common Stock (DE) $375.85 +1.32% NVS Novartis AG $143.67 +0.39% AZN AstraZeneca PLC $159.80 +0.64% TMO Thermo Fisher Scientific Inc $658.03 +0.93% AMGN Amgen Inc. $411.71 +1.05% GILD Gilead Sciences, Inc. $150.24 +2.13% ABT Abbott Laboratories $99.70 +1.22% NVO Novo Nordisk A/S $38.39 +0.54%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides